In vivo selection of retrovirally transduced hematopoietic stem cells

Nature Medicine

Volumn 4, Issue 10, 1998, Pages 1136-1143

  Allay, James A ^a   Persons, Derek A ^a   Galipeau, Jacques ^a   Riberdy, Janice M ^a   Ashmun, Richard A ^a   Blakley, Raymond L ^a   Sorrentino, Brian P ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLOOD DISEASE; GENE THERAPY; GENETIC STABILITY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RETROVIRUS; VIRUS CELL INTERACTION;

ANIMALS; BLOOD CELLS; DRUG RESISTANCE; FEMALE; FOLIC ACID ANTAGONISTS; GENE THERAPY; GENES, REPORTER; GENETIC VECTORS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MICE; MICE, INBRED C57BL; RETROVIRIDAE; SELECTION (GENETICS); TETRAHYDROFOLATE DEHYDROGENASE; THIOINOSINE; THIONUCLEOTIDES; TRANSFORMATION, GENETIC; TRIMETREXATE;

UNIDENTIFIED RETROVIRUS;

EID: 0031721636     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/2632     Document Type: Article

References (34)

1. Karlsson, S. Treatment of genetic defects in hematopoietic cell function by gene transfer. Blood 78, 2481-2492 (1991).
2. Dick, J.E., Magli, M.C., Huszar, D., Phillips, R.A. & Bernstein, A. Introduction of a selectable gene into primitive stem cells capable of long-term reconstitution of the hemopoietic system of W/Wv mice. Cell 42, 71-79 (1985).
3. Williams, D.A., Lemischka, I.R., Nathan, D.G. & Mulligan, R.C. Introduction of new genetic material into pluripotent haematopoietic stem cells of the mouse. Nature 310, 476-480 (1984).
4. Lemischka, I.R., Raulet, D.H. & Mulligan, R.C. Developmental potential and dynamic behavior of hematopoietic stem cells. Cell 45, 917-927 (1986).
5. Dunbar, C.E. et al. Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. Blood 85, 3048-3057 (1995).
6. Brenner, M.K. et al. Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients. Lancet 342, 1134-1137 (1993).
7. Sorrentino, B.P. et al. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science 257, 99-103 (1992).
8. Podda, S. et al. Transfer and expression of the human multiple drug resistance gene into live mice. Proc. Natl. Acad. Sci. USA. 89, 9676-9680 (1992).
9. Corey, C.A., DeSilva, A.D., Holland, C.A. & Williams, D.A. Serial transplantation of methotrexate-resistant bone marrow: protection of murine recipients from drug toxicity by progeny of transduced stem cells. Blood 75, 337-343 (1990).
10. Zhao, S.C. et al. Long-term protection of recipient mice from lethal doses of methotrexate by marrow infected with a double-copy vector retrovirus containing a mutant dihydrofolate reductase. Cancer Gene Ther. 1, 27-33 (1994).
11. Allay, J.A., Davis, B.M. & Gerson, S.L. Human alkyltransferase-transduced murine myeloid progenitors are enriched in vivo by BCNU treatment of transplanted mice. Exp. Hematol. 25, 1069-1076 (1997).
12. Davis, B.M. et al. Selection for G156A O6-methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and protection from lethality in mice treated with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res. 57, 5093-5099 (1997).
13. Maze, R. et al. Reversal of 1,3-bis(2-chloroethyl)-1-nitrosourea-induced severe immunodeficiency by transduction of murine long-lived hemopoietic progenitor cells using O6-methylguanine DNA methyltransferase complementary DNA. J. Immunol, 158, 1006-1013 (1997).
14. Li, M.X. et al. Development of a retroviral construct containing a human mutated dihydrofolate reductase cDNA for hematopoietic stem cell transduction. Blood 83, 3403-3408 (1994).
15. Spencer, H.T., Sleep, S.E., Rehg, J.E., Blakley, R.L. & Sorrentino, B.P. A gene transfer strategy for making bone marrow cells resistant to trimetrexate. Blood 87, 2579-2587 (1996).
16. Blau, C.A., Neff, T. & Papayannopoulou, Th. The hematologic effects of folate analogs: implications for using the dihydrofolate reductase gene for in vivo selection. Hum. Gene Ther. 7, 2069-2078 (1996).
17. Belt, J.A., Marina, N.M., Phelps, D.A. & Crawford, C.R. Nucleoside transport in normal and neoplastic cells. Adv. Enzyme Regul. 33, 235-252 (1993).
18. Allay, J.A. et al. Sensitization of hematopoietic stem and progenitor cells to trimetrexate using nucleoside transport inhibitors. Blood 90, 3546-3554 (1997).
19. Pawliuk, R., Kay, R., Lansdorp, P. & Humphries, R.K. Selection of retrovirally transduced hematopoietic cells using CD24 as a marker of gene transfer. Blood 84, 2868-2877 (1994).
20. Lewis, W.S. et al. Methotrexate-resistant variants of human dihydrofolate reductase with substitutions of leucine 22. Kinetics, crystallography, and potential as selectable markers. J. Biol. Chem. 270, 5057-5064 (1995).
21. Hawley, R.G., Fong, A.Z., Burns, B.F. & Hawley, T.S. Transplantable myeloproliferative disease induced in mice by an interleukin 6 retrovirus. J. Exp. Med. 176, 1149-1163 (1992).
22. Pawliuk, R., Eaves, C.J. & Humphries, R.K. Sustained high-level reconstitution of the hematopoietic system by preselected hematopoietic cells expressing a transduced cell-surface antigen. Hum. Gene Ther. 8, 1595-1604 (1997).
23. Persons, D.A. et al. Retroviral-mediated transfer of the green fluorescent protein gene into murine hematopoietic cells facilitates scoring and selection of transduced progenitors in vitro and identification of genetically modified cells in vivo. Blood 90, 1777-1786 (1997).
24. Harrison, D.E. Competitive repopulation: a new assay for long-term stem cell functional capacity. Blood 55, 77-81 (1980).
25. Jordan, C.T. & Lemischka, I.R. Clonal and systemic analysis of long-term hematopoiesis in the mouse. Genes Dev. 4, 220-232 (1990).
26. Challita, P.M. & Kohn, D.B. Lack of expression from a retroviral vector after transduction of murine hematopoietic stem cells is associated with methylation in vivo. Proc. Natl. Acad. Sci. USA. 91, 2567-2571 (1994).
27. Molineux, G., Migdalska, A., Haley, J., Evans, G.S. & Dexter, T.M. Total marrow failure induced by pegylated stem-cell factor administered before 5-fluorouracil. Blood 83, 3491-3499 (1994).
28. Blau, C.A., Neff, T. & Papayannopoulou, T. Cytokine prestimulation as a gene therapy strategy: implications for using the MDR1 gene as a dominant selectable marker. Blood 89, 146-154 (1997).
29. Willson, J.K. et al. Methotrexate and dipyridamole combination chemotherapy based upon inhibition of nucleoside salvage in humans. Cancer Res. 49, 1866-1870 (1989).
30. Rongen, G.A. et al. Hemodynamic and neurohumoral effects of various grades of selective adenosine transport inhibition in humans. Implications for its future role in cardioprotection. J. Clin. Invest. 95, 658-668 (1995).
31. Morgan, R.A. et al. Retroviral vectors containing putative internal ribosome entry sites: development of a polycistronic gene transfer system and applications to human gene therapy. Nucleic Acids Res. 20, 1293-1299 (1992).
32. Bunting, K.D., Sangster, M.Y., Ihle, J.N. & Sorrentino, B.P. Restoration of lymphocyte function in Janus kinase 3-deficient mice by retroviral-mediated gene transfer. Nature Med. 4, 58-64 (1998).
33. Whitney, J.B. Simplified typing of mouse hemoglobin (Hbb) phenotypes using cystamine. Biochem. Genet. 16, 667-672 (1978).
34. Lynch, T.P., Paran, J.H. & Paterson, A.R. Therapy of mouse leukemia L1210 with combinations of nebularine and nitrobenzylthioinosine 5′-monophosphate. Cancer Res. 41, 560-565 (1981).